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Abstract
Burkholderia contaminans is a member of the Burkholderia cepacia complex (Bcc), a pathogen with increasing preva-
lence among cystic fibrosis (CF) patients and the cause of numerous outbreaks due to the use of contaminated commercial 
products. The antibiotic resistance determinants, particularly β-lactamases, have been poorly studied in this species. In this 
work, we explored the whole genome sequence (WGS) of a B. contaminans isolate (FFH 2055) and detected four putative 
β-lactamase-encoding genes. In general, these genes have more than 93% identity with β-lactamase genes found in other Bcc 
species. Two β-lactamases, a class A (Pen-like, suggested name PenO) and a class D (OXA-like), were further analyzed and 
characterized. Amino acid sequence comparison showed that Pen-like has 82% and 67% identity with B. multivorans PenA 
and B. pseudomallei PenI, respectively, while OXA-like displayed strong homology with class D enzymes within the Bcc, 
but only 22–44% identity with available structures from the OXA family. PCR reactions designed to study the presence of 
these two genes revealed a heterogeneous distribution among clinical and industrial B. contaminans isolates. Lastly, blaPenO 
gene was cloned and expressed into E. coli to investigate the antibiotic resistance profile and confers an extended-spectrum 
β-lactamase (ESBL) phenotype. These results provide insight into the presence of β-lactamases in B. contaminans, suggest-
ing they play a role in antibiotic resistance of these bacteria.
Introduction
Cystic fibrosis (CF) is a genetic disorder that affects approxi-
mately 70,000–100,000 people worldwide, imposing a life-
limiting condition to patients harboring this disorder [1]. Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s0028 4-019-01653 -4) contains 
supplementary material, which is available to authorized users.
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In persons with CF, Pseudomonas aeruginosa is one of the 
most important pathogens that can cause life-threatening 
infections. Regrettably, many other bacterial genera have 
also emerged as significant pathogens in persons with CF 
[2]. Moreover, prolonged antibiotic therapy received by 
these patients is a propitious scenario for the evolution of 
antibiotic resistant pathogens [3].
The Burkholderia cepacia complex (Bcc) is composed 
of >20 closely related species that are opportunistic human 
pathogens that mainly have a significant impact in patients 
with CF [4]. The Bcc complex is resistant to a wide range of 
antibiotics, and therefore infections caused by these bacte-
ria are very difficult to eradicate. Strikingly, infections may 
derive into “cepacia syndrome” with fatal consequences 
(necrotizing pneumonia, respiratory failure, and sepsis/
bacteremia) [5–7]. An additional negative aspect of the 
Bcc is their ability to contaminate man-made products such 
as pharmaceuticals, cosmetics, and disinfectants [4, 8, 9]. 
Nosocomial outbreaks due to the use of Bcc contaminated 
products are often reported [10].
Since B. cenocepacia and B. multivorans are the most 
prevalent Bcc among persons with CF in the United States, 
Canada, France, United Kingdom, and Belgium, these Bcc 
species are well studied and characterized [11–13]. How-
ever, in recent years, B. contaminans, a species defined in 
2009, has been widely identified as a nosocomial opportun-
istic pathogen of rising importance due to outbreaks that 
took place in different parts of the world [14]. Presently, B. 
contaminans is reported as the most frequent Bcc species 
isolated in CF patients from Portugal, Spain, and Argentina, 
and is associated with infections in immunocompromised 
and hospitalized patients exposed to contaminated products 
in Germany and United States [15–20]. Due to its recent 
speciation, few studies are available on B. contaminans, and 
little is known about its virulence factors, susceptibility to 
antibiotics, prognosis of infected patients, and other issues of 
clinical relevance [21]. Recently, whole genome sequencing 
was performed on several B. contaminans strains and these 
sequences are available in the GenBank database [22–24].
As with all Bcc members, B. contaminans possesses 
innate resistance to a wide range of antimicrobials; as a 
result, the clinical treatment of infections is problematic. 
The main antibiotic resistance mechanisms described in 
Bcc include the unique structure of the lipopolysaccharide 
(LPS) in the outer membrane, the presence of efflux pumps, 
the degradation of antibiotics by means of enzymes such as 
β-lactamases, and the ability to form biofilms [25]. Adding 
to this, Bcc displays the possibility to acquire even more 
antibiotic resistant determinants through horizontal gene 
transfer [26, 27].
Among the antibiotic resistance mechanisms mentioned 
above, β-lactamases are not well characterized in Bcc. 
Inducible chromosomal class A β-lactamases (PenA and 
PenB) were investigated in B. cenocepacia and B. multi-
vorans and are reported in other Bcc members [28–32]. Most 
studies focused on studying this single class A β-lactamase, 
as it appears to be the dominant β-lactam resistance mecha-
nism in Bcc. However, the genomes of Bcc harbor other 
putative β-lactamase (bla) genes. For instance, in the study 
describing the whole genome of B. cenocepacia J2315, at 
least four bla genes encoding potential β-lactamases were 
found though their activity is not yet established [33]. With 
regard to B. contaminans, studies on β-lactamases have not 
been conducted. The presence of genes associated with 
β-lactamases is mentioned in a work describing the genome 
of B. contaminans MS14, an isolate obtained from soil, 
but the number of genes and the characterization of these 
enzymes was not pursued [22].
In this work, we explore the genome of the B. contami-
nans strain FFH 2055 that was isolated from the sputum 
of a person with CF in Argentina [34]. We determined the 
presence of four putative β-lactamase genes in B. contami-
nans strain FFH 2055 and conducted comparative analyses 
of the bla genes with other Bcc and non-Bcc species. The 
presence of select bla genes was further explored within 
46 B. contaminans isolates. In addition, molecular models 
were generated of the class D OXA β-lactamase as well as 
the class A Pen-like β-lactamase, which based on previous 
nomenclature in the Bcc field, will be denoted as PenO [35]. 
As the Pen-like β-lactamases are the dominant β-lactam 
resistance mechanism in Burkholderia spp., the antibiotic 
resistance profile of PenO was further evaluated by cloning 
and expressing blaPenO in Escherichia coli.
Materials and Methods
Bacterial Strain and Genome Sequences
Burkholderia contaminans FFH 2055 was isolated from spu-
tum of a 6-year-old girl with CF in Argentina. The patient 
was chronically infected with this species until her death 
at the age of 12. The strain was preserved at − 80 °C in 
Tryptic Soy Broth (TSB) with 40% glycerol for future stud-
ies. The draft genome of FFH 2055 was recently published 
[34]. Sequences were retrieved from GenBank (accession 
LASC01000001 to LASC01000008) and analyzed to search 
for putative bla genes using the RAST server [36, 37]. Also, 
46 B. contaminans isolates obtained from persons with CF 
(n = 21), non-CF patient comparators (n = 13), and industrial 
contaminated products (n = 12) were employed to investigate 
the distribution of blaPenO and blaOXA-like genes (Table 1).
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Bioinformatics Analysis
The nucleotide and translated amino acid sequences of the 
putative β-lactamase-encoding genes in B. contaminans 
FFH 2055 were investigated in genome sequences of other 
B. contaminans strains as well as other Bcc species by per-
forming BLAST N searches in GenBank and the Burkholde-
ria.com database [38]. A gene encoding a Pen-like class A 
β-lactamase (WR30_RS27340, named blaPenO) was selected 
for further studies. Translated amino acid sequences were 
analyzed using NCBI BLAST X 2.7.0+ [39]. Sequence and 
structural alignments of amino acid sequences were per-
formed using T-Coffee Expresso and ESPript/ENDscript 
[40, 41].
Protein Structure Prediction and Molecular 
Modeling of Hypothetical Pen‑Like and OXA‑Like 
β‑Lactamases
A prediction of the α-helical content of PenO was performed 
with AGADIR software [42], and theoretical three-dimen-
sional (3D) models for the enzyme were predicted by using 
the Swiss-Model tool (http://swiss model .expas y.org) and 
Yasara, using a standard homology modeling protocol [43]. 
All models were visualized with PyMOL 1.6 [44].
General Molecular Biology Techniques
The blaPenO gene was amplified by PCR reaction using 
primers listed in Table S1 and cloned into the pBC SK(+) 
vector  (CHLR) (Adgene). E. coli TOP10 cells were then 
transformed with the pBC SK(+) blaPenO (pblapenO) and 
antibiotic susceptibility tests were performed (see below).
In addition, PCR reactions were used to detect the bla-
PenO and blaOXA-like genes among a collection of B. contam-
inans isolates. Primers employed in these reactions were 
designed using Primer 3 software (v 0.4.0) and are listed in 
Table S1 [45, 46]. B. contaminans isolates were suspended 
in sterile distilled water, boiled for 10 min, and centrifuged 
at 14000 rpm for 5 min. A 5 µl bacterial suspension was 
used to carry out PCR reactions. Cycling conditions were 
94 °C for 2 min; 30 cycles of 94 °C for 1 min, annealing 
temperature for 1 min, and 72 °C for 1 min; and finally, 
72 °C for 10 min.
Antimicrobial Susceptibility Testing
Disk diffusion assays with various β-lactam antibiotics 
(AMP: ampicillin; AMC: amoxicillin-clavulanate; CTX: 
cefotaxime; CRO: ceftriaxone; CAZ: ceftazidime; CZ: 
cefazolin; FEP: cefepime; FOX: cefoxitin; IMP: imipe-
nem; MEM: meropenem) were performed following the 
Clinical and Laboratory Standards Institute (CLSI) guide-
lines (Table 2) [47]. The disk diffusion tests served as 
a screening tool to determine potential substrates for the 
enzyme. Minimum inhibitory concentrations (MIC) by E 
Table 1  Putative β-lactamases in B. contaminans FFH2055 and % identity to non-Bcc and Bcc species
Putative β-lactamase genes in 
B. contaminans FFH2055 
Locus tag
(bp length)
Amino acid comparison in 
GenBank
Best match % of identity 
accession product
Nucleotide comparison in Burkholderia.com % identity
Locus tag
Best match Identity with B. 
cenocepacia J2315
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test for AMP, CAZ, MEM, and IMP were also performed 
as recommended.
Results
Putative β‑Lactamases Present in the B. 
contaminans FFH 2055 Genome
The total number of putative bla genes in B. contami-
nans FFH 2055 genome was eighteen. However, non-β-
lactamases, such as hydrolases and proteases, possess simi-
lar structures/amino acid sequences to β-lactamases; thus, 
proteins are often annotated as β-lactamases, even though 
they are not actually β-lactamases. As a result, a second-
ary analysis for the presence of a signal peptide as well 
as conserved β-lactamase motifs in translated amino acid 
sequences was conducted. As β-lactamases are periplasmic 
enzymes, they must possess a signal peptide (analysis tool: 
SignalP 4.1 Server). Analysis of the signal peptides in the 18 
putative β-lactamases reduced the list to 5 β-lactamases (two 
class A enzymes, one class B, one class C, and one class 
D). Each β-lactamase class possesses conserved motifs that 
can be used to further identify potential β-lactamases. The 
following motifs should be present within each class: class 
A: SXXK motif, SDN loop, RXEXXXXXXXXXXXXD 
Ω-loop, and KTG motif; class B: HXHXD motif; class 
C: SXXK motif, YSN motif, and KTG motif; and class 
D: SXXK motif and KTG motif. Of the two class A 
β-lactamases, one lacked the SXXK, SDN, and KTG motifs, 
and thus was removed from the list.
As a result of this analysis, four putative bla genes were 
identified in B. contaminans FFH 2055. These genes encode 
for putative class A Pen-like (WR30_RS27340), class B 
(WR30_RS21040), class C (WR30_RS20060), and class D 
OXA (WR30_RS31065) β-lactamases (Table 1). The nucle-
otide sequences of WR30_RS27340 and WR30_RS20060 
were found in all other B. contaminans genomes currently 
deposited in GenBank (n = 17) with 95–100% identity. 
Meanwhile, WR30_RS21040 and WR30_RS31065 were 
detected in one and 12 genomes (100% and 95–100% iden-
tity), respectively.
Comparative Analysis of the Four β‑Lactamase 
Amino Acid and Nucleotide Sequences to Non‑Bcc 
and Bcc
To further investigate these β-lactamases, a comparison to 
non-Burkholderial as well as Bcc β-lactamases was con-
ducted using the GenBank and Burkholderia.com databases. 
According to GenBank, the four B. contaminans FHH 2055 
β-lactamases were found to be most similar to bacteria (i.e., 
Jeongeupia sp. USM3, Amantichitinum ursilacus, Voge-
sella sp. LIG4, and Klebsiella michiganensis) isolated from 
environmental sources with amino acid sequence identity 
ranging from 55 to 65% (Table 1). A BLAST search of the 
Burkholderia.com database demonstrated that three of bla 
nucleotide sequences shared more than 93% identity with 
β-lactamase-encoding genes found in other Bcc species 
(Table 1). Only the gene coding for a putative metallo-β-
lactamase (class B β-lactamase) displayed a lower identity 
with the closest match to a B. vietnamiensis strain (79.7% 
identity). The highest identity of individual genes was found 
within B. cepacia and B. lata strains (Table 1).
Furthermore, a BLAST search at amino acid level using 
the four putative β-lactamases detected in B. contaminans 
FFH 2055 revealed that two of them (class A and class C 
β-lactamase) were also found in all the Bcc species avail-
able genomes in the GenBank (only B. arboris does not 
have sequenced genomes submitted) with more than 75% 
and 40% of coverage and identity, respectively. The Pen-
like class A β-lactamase is critical for β-lactam resistance 
in Bcc, while the class C β-lactamase, which was character-
ized in B. multivorans, may not actually be a β-lactamase, 
Table 2  Origin, source, and distribution of blaPenO and blaOXA-like genes among B. contaminans isolates
Isolates Distribution of blaPenO and blaOXA-like








CF patients (21) Children’s Hospital Juan P. Garrahan (9) 8 0 0 1
Children’s Hospital Ricardo Gutierrez (12) 10 1 0 1
Non-CF patients (13) University Hospital José de San Martín (5) 5 0 0 0
Hospital Ramos Mejía (5) 4 0 1 0
Children’s Hospital Ricardo Gutierrez (3) 3 0 0 0
Industrial (12) Purified water and facilities (5) 4 0 0 1
Pharmaceutical products (3) 1 1 0 1
Ultrasound gel (1) 1 0 0 0
Disinfectants and housecleaners (3) 1 1 1 0
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but a low molecular mass penicillin binding protein; further 
studies are in progress (References: PMID: 30012762 and 
29983287). The class B β-lactamase was not detected in B. 
multivorans, B. dolosa, B. latens, B. metallica, B. seminalis, 
B. lata, B. metallica, B. pseudomultivorans, B. stagnalis, and 
B puraquae. With respect to the class D β-lactamases, none 
were detected in B. vietnamiensis, B. dolosa, B ambifaria, 
and B. latens (Figure S1). Of the β-lactamases, the class A 
β-lactamase and class C β-lactamase are most prevalent in 
Bcc.
As B. cenocepacia and B. multivorans are the most preva-
lent species in Europe and North America, the four puta-
tive β-lactamase genes were compared to the type strain 
of these species (B. cenocepacia J2315 and B. multivorans 
ATCC 17616). The four bla genes found in B. contami-
nans FFH 2055 shared between 70% and 90% identity with 
genes of B. cenocepacia, while the blaOXA-like and the class 
B β-lactamase genes were not found in the B. multivorans 
strain (Table 1). Interestingly, the B. cenocepacia genes that 
shared similarity with blaPenO and class B β-lactamase were 
not annotated as β-lactamases when genome of B. cenoce-
pacia J2315 was described [33].
Distribution of  blaPenO and  blaOXA‑like Genes Among 
B. contaminans Isolates
We decided to focus our studies on two selected bla 
genes, named blaPenO and blaOXA-like, coding for a class A 
β-lactamase and a class D β-lactamase, respectively. PenO 
was selected, because it is the dominant β-lactamase in Bcc. 
As evidence to date suggests that the class C β-lactamase 
may not function as a β-lactamase (PMID: 30012762), the 
OXA-like β-lactamase was also selected for analysis as it is 
next most often detected β-lactamase in Bcc.
By PCR reactions, blaPenO and blaOXA-like genes were 
detected in most of the B. contaminans isolates evaluated 
(84.8% blaPenO positive reactions and 87% blaOXA-like posi-
tive reactions). Slight differences were observed consider-
ing the origin of the isolates. Both PCR reactions yielded 
an amplification product in 37 out of 46 isolates (18 from 
21 CF isolates, 12 from 13 clinical non-CF isolates, 7 from 
12 industrial isolates), while in two isolates collected from 
CF patients and two clinical isolates, both PCR reactions 
resulted in negative results (Table 2). The highest percent-
age of isolates lacking one of these genes was obtained 
among industrial isolates (33.3% blaPenO and 25% blaOXA-like, 
respectively). On the other hand, the clinical isolates 
obtained from non-CF patients accounted the highest per-
centage of positive amplification for blaPenO and blaOXA-like, 
with only one isolate displaying a negative amplification 
result for blaOXA-like. We note that sequence heterogeneity 
within the blaPenO and blaOXA-like genes may have limited 
the detection of some of these bla genes in the isolates [35].
Genetic Environment of  blaPenO and  blaOXA‑like
The surrounding of blaPenO gene displayed homologous 
sequences from the environment of blapenB previously 
described in B. cenocepacia (Figure S2) [29]. A gene encod-
ing a putative LysR regulator (PenR) (WR30_RS27345) is 
located upstream and is transcribed in an opposite orienta-
tion of blaPenO. The nucleotide sequence of this gene shares 
more than 94% identity with LysR encoding genes detected 
in B. lata, B. cepacia, and B. cenocepacia strains among 
other Bcc species. The 127-bp intergenic sequence between 
blaPenO and penR gene also revealed 85% similarity with 
the intergenic region of B. cenocepacia J2315 displaying 
identical sequences for the two putative − 10 and − 35 pro-
moter boxes and the two potential ribosome-binding sites 
described (Fig. S2) [29].
Regarding blaOXA-like genetic environment, it is closely 
related to strains of other Bcc species like B. cepacia, B. 
cenocepacia, and B. multivorans, flanked by a putative acyl-
transferase and a putative porin gene (Fig. S3). Although 
previous described promoters were not detected in the 
upstream intergenic region, a BLAST comparison of this 
327 bp did not reveal any matches with non-Burkholderia 
species, but shares more than 80% identity with sequences 
of B. cenocepacia, B. cepacia, and B. lata strains among 
other Bcc species, located upstream of a putative class D 
β-lactamase gene (Fig. S3). In addition, insertion sequences, 
transposons, or other mobile elements were not detected 
around blaPenO and blaOXA-like (data not shown).
Amino Acid Sequence Analysis and Molecular 
Modeling of PenO and OXA‑Like β‑Lactamases
Compared to other class A β-lactamases, B. contaminans 
PenO enzyme possesses all the conserved residues and 
motifs that model the active site (Fig. 1a): motif 1 containing 
the active-site serine (S70) residue (STFK); motif 2 (SDN); 
motif 3 (KTG); and a Ω-loop including the essential glu-
tamic acid residue (E166). According to the amino acid rela-
tionship with other class A enzymes (Fig. 1b), B. contami-
nans PenO possesses 82% and 67% amino acid identity with 
B. multivorans PenA and B. pseudomallei PenI enzymes, 
respectively [30], and whose crystallographic structures 
were also solved (PDB 3W4Q and 3W4O). Regarding other 
Pen-like β-lactamases described in Bcc members, amino 
acid identities ranges from 74% (B. ubonensis PenH) to 
88% (B. cenocepacia PenB1). In comparison with non-Bcc 
Burkholderia species, PenO displays identities from 57% (B. 
gladioli PenN) to 63% (B. thailandensis PenL). PenO also 
showed 55–57% amino acid identity with extended-spectrum 
CTX-M β-lactamases, and shares some common residues 
with PER enzymes, essential for the active-site coordination 
(see below).
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On the other hand, B. contaminans OXA-like β-lactamase 
showed the class D conserved motifs (Fig. 1a): STFK (motif 
1) containing the active-site serine (S70); YGN (motif 2); 
and KTG (motif 3). OXA-like β-lactamase displayed sig-
nificant homology with class D enzymes within the Bcc, 
52–55% amino acid identity with OXA-57 from B. pseu-
domallei, although only 22–44% amino acid identity with 
available structures from the OXA family, being closely 
related to OXA-45 and related enzymes (Fig. 1b).
In silico molecular modeling of both PenO and OXA-like 
showed that these β-lactamases possess the typical overall 
fold of other class A and D β-lactamases, respectively, being 
the active-site cavity located between the “all α” and the 
“α/β” domains (Fig. 2).
In PenO, the active site is composed of conserved residues 
that are also found in other class A β-lactamases (Fig. 2b). 
Among the most interesting features, the presence of R220 
(also found in Pen β-lactamases) and D240 are highlighted. 
A conserved arginine is found in most clinically important 
ESBL, i.e., CTX-M (R276), TEM/SHV (R244), and PER 
(R220) whose guanidinium lateral chain always points towards 
the active site [48–50]; as in the case of PER β-lactamases, 
R220 could also create a hydrogen bond network essential for 
the activity in Pen β-lactamases [51]. An aspartic acid resi-
due at 240 is commonly found in enzymes like the cefotax-
ime-hydrolyzing CTX-M, which is replaced by a glycine in 
those variants having a slight “ceftazidimase” behavior [52, 
53]. Interestingly, the putative Ω-loop fold seems to create 
a broader active-site cavity compared to extended-spectrum 
CTX-M β-lactamases, which together with the residues men-
tioned above could contribute to an efficient hydrolysis towards 
some β-lactams. Noteworthy is the presence of a threonine at 
167 (also observed in PenA) replacing the conserved proline in 
Fig. 1  a Multiple sequence alignment of PenO and OXA-like and 
other related class A and D β-lactamases, respectively, were con-
structed with ESPript 3.0 (http://espri pt.ibcp.fr/ESPri pt/ESPri pt/) 
and showed the regions containing the conserved active-site resi-
dues. Yellow boxes indicate the putative conserved motifs. Second-
ary structure is provided only for PenO, which possesses high homol-
ogy with the reference sequence/model. b Neighbor-joining-based 
tree showing the amino acid sequence relationship of both enzymes 
with the closest β-lactamases. Sequences included were selected from 
the closest enzymes according to the Blast result. For those enzymes 
which are species-specific, the species name is provided in parenthe-
sis: Bco: B. contaminans; Bmu: B. multivorans; Bps: B. pseudomal-
lei. (Color figure online)
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most class A β-lactamases, which could influence the folding 
of the Ω-loop and probably also in the activity.
Remarkably, the OXA-like β-lactamase includes interesting 
structural features that deserve further analysis. Apart from the 
conserved residues usually found in class D enzymes (Figs. 1, 
2), OXA-like β-lactamase remarkably carries a six-residue 
insertion after the YGN conserved motif (PAGELN), which is 
also found in OXA-45 (EPGKSN) [54]. As in other clinically 
important OXAs, including OXA-48-derived carbapenemases, 
OXA-like β-lactamase presents several mutations in the β4–β5 
loop [55]; as in OXA-45, this “hot spot” region is composed of 
ten residues compared to five in OXA-48, OXA-24, and OXA-
51 carbapenemases, while in OXA-2 and OXA-163 there is 
only one residue (data not shown).
Antimicrobial Phenotypic Profile of PenO 
β‑Lactamase
As the Pen-like β-lactamases are present in all Bcc, the 
antimicrobial resistance profile of PenO β-lactamase was 
determined. Disk diffusion assays using several β-lactam 
antibiotics against the parent B. contaminans FHH 2055 
and E. coli TOP10 cells containing plasmid, pblaPenO, were 
determined according to CLSI guidelines [47]. CLSI only 
provides breakpoints for ceftazidime, meropenem, and ticar-
cillin-clavulanic acid for Bcc. Thus, β-lactam breakpoints for 
Enterobacteriaceae were used to assist interpretation of the 
resistance profiles.
The B. contaminans strain demonstrated resistance 
towards ampicillin, amoxicillin-clavulanic acid, cefazolin, 
cefoxitin, cefotaxime, and ceftriaxone (Table 3). Compared 
to E. coli TOP10 harboring the empty vector, changes in 
the inhibition zones were observed for ampicillin, amox-
icillin-clavulanic acid, cefazolin, cefoxitin, cefotaxime, 
ceftriaxone, and cefepime, when pblaPenO plasmid was 
introduced (Table 3). Thus, PenO behaves similarly to an 
extended-spectrum β-lactamase (ESBL). MIC results were 
also obtained for the E. coli strains and E. coli with pblaPenO 
possessed higher MICs towards all the β-lactams tested with 
the exception of carbapenems (Table 4).
Fig. 2  Left: theoretical molecular model of PenO (up) and OXA-
like (down) β-lactamases, indicating the active-site entry (orange 
arrow); Middle: detail of the active-site coordination, indicating con-
served or important residues for the structure and function of class A 
β-lactamases; right: comparison of PenO vs CTX-M-96 (PDB 3ZNY) 
and PenA (PDB 3W4Q), and OXA-like vs OXA-48 (PDB 3HBR). 
(Color figure online)
 J. J. Degrossi et al.
1 3
Conclusion
Although class A β-lactamases of the Pen family were 
reported in Bcc species and PenA in B. multivorans was 
studied and characterized, the knowledge about other 
β-lactamases in the Bcc is scarce [31, 55]. Particularly, stud-
ies are not available about these enzymes in B. contaminans, 
an emerging opportunistic pathogen that is also frequently 
recovered from contaminated products. The analysis of B. 
contaminans FFH 2055 revealed the presence of at least four 
putative genes coding different classes of these enzymes. A 
comparative analysis with other Bcc genomes demonstrated 
the presence, although not homogeneously, of a similar num-
ber of putative β-lactamases genes in other Bcc species. A 
deeper study of two of these genes, blaPenO and blaOXA-like, 
allowed us to report the relationship with other β-lactamases, 
the hypothetical structure of its products, and to hypothesize 
that a heterogeneous distribution of these genes may occur 
among B. contaminans isolates. According to nomenclature 
of Pen-like family described in the Burkholderia genus, the 
name of PenO is suggested for class A β-lactamase detected 
in B. contaminans. The antibiotic susceptibility testing sug-
gested that PenO is likely an ESBL.
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